Inhibition of VEGF blocks TGF-β 1 production through a PI3K/Akt signalling pathway

K. S. Lee, S. J. Park, S. R. Kim, Kyung-Hoon Min, K. Y. Lee, Y. H. Choe, S. H. Hong, Y. R. Lee, J. S. Kim, S. J. Hong, Y. C. Lee

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

Vascular endothelial growth factor (VEGF) is a mediator of airway inflammation and remodelling in asthma. Transforming growth factor (TGF)-β 1 plays pivotal roles in diverse biological processes, including tissue remodelling and repair in a number of chronic lung diseases. However, there are few studies elucidating the interactions between VEGF and TGF-β 1 in allergic airway disease. A murine model of allergic airway disease was used to define the mechanism by which VEGF induces subepithelial fibrosis and to investigate a potential relationship between VEGF and TGF-β 1 and the mechanisms by which VEGF signalling regulates TGF-β 1 expression in allergic airway disease. The ovalbumin (OVA)-inhaled murine model revealed the following typical pathophysiological features of allergic airway disease in the lungs: increased numbers of inflammatory cells of the airways, airway hyperresponsiveness, increased peribronchial fibrosis, and increased levels of VEGF and TGF-β 1. Administration of VEGF inhibitors reduced the pathophysiological signs of allergic airway disease and decreased the increased TGF-β 1 levels and peribronchial fibrosis, including phosphoinositide 3-kinase (PI3K) activity after OVA inhalation. In addition, the increased TGF-β 1 levels and collagen deposition after OVA inhalation were decreased by administration of PI3K inhibitors. These results suggest that inhibition of vascular endothelial growth factor attenuates peribronchial fibrosis, at least when mediated by regulation of transforming growth factor-β 1 expression through phosphoinositide 3-kinase/Akt pathway in a murine model of allergic airway disease. Copyright

Original languageEnglish
Pages (from-to)523-531
Number of pages9
JournalEuropean Respiratory Journal
Volume31
Issue number3
DOIs
Publication statusPublished - 2008 Mar 1
Externally publishedYes

Fingerprint

1-Phosphatidylinositol 4-Kinase
Transforming Growth Factors
Vascular Endothelial Growth Factor A
Ovalbumin
Fibrosis
Inhalation
Lung Diseases
Airway Remodeling
Biological Phenomena
Inflammation Mediators
Chronic Disease
Collagen
Asthma
Cell Count

Keywords

  • Airway remodelling
  • Phosphoinositide 3-kinase
  • Subepithelial fibrosis
  • Transforming growth factor-β
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Inhibition of VEGF blocks TGF-β 1 production through a PI3K/Akt signalling pathway. / Lee, K. S.; Park, S. J.; Kim, S. R.; Min, Kyung-Hoon; Lee, K. Y.; Choe, Y. H.; Hong, S. H.; Lee, Y. R.; Kim, J. S.; Hong, S. J.; Lee, Y. C.

In: European Respiratory Journal, Vol. 31, No. 3, 01.03.2008, p. 523-531.

Research output: Contribution to journalArticle

Lee, KS, Park, SJ, Kim, SR, Min, K-H, Lee, KY, Choe, YH, Hong, SH, Lee, YR, Kim, JS, Hong, SJ & Lee, YC 2008, 'Inhibition of VEGF blocks TGF-β 1 production through a PI3K/Akt signalling pathway', European Respiratory Journal, vol. 31, no. 3, pp. 523-531. https://doi.org/10.1183/09031936.00125007
Lee, K. S. ; Park, S. J. ; Kim, S. R. ; Min, Kyung-Hoon ; Lee, K. Y. ; Choe, Y. H. ; Hong, S. H. ; Lee, Y. R. ; Kim, J. S. ; Hong, S. J. ; Lee, Y. C. / Inhibition of VEGF blocks TGF-β 1 production through a PI3K/Akt signalling pathway. In: European Respiratory Journal. 2008 ; Vol. 31, No. 3. pp. 523-531.
@article{f93139eab6b54f1885dd1278f0b70f6b,
title = "Inhibition of VEGF blocks TGF-β 1 production through a PI3K/Akt signalling pathway",
abstract = "Vascular endothelial growth factor (VEGF) is a mediator of airway inflammation and remodelling in asthma. Transforming growth factor (TGF)-β 1 plays pivotal roles in diverse biological processes, including tissue remodelling and repair in a number of chronic lung diseases. However, there are few studies elucidating the interactions between VEGF and TGF-β 1 in allergic airway disease. A murine model of allergic airway disease was used to define the mechanism by which VEGF induces subepithelial fibrosis and to investigate a potential relationship between VEGF and TGF-β 1 and the mechanisms by which VEGF signalling regulates TGF-β 1 expression in allergic airway disease. The ovalbumin (OVA)-inhaled murine model revealed the following typical pathophysiological features of allergic airway disease in the lungs: increased numbers of inflammatory cells of the airways, airway hyperresponsiveness, increased peribronchial fibrosis, and increased levels of VEGF and TGF-β 1. Administration of VEGF inhibitors reduced the pathophysiological signs of allergic airway disease and decreased the increased TGF-β 1 levels and peribronchial fibrosis, including phosphoinositide 3-kinase (PI3K) activity after OVA inhalation. In addition, the increased TGF-β 1 levels and collagen deposition after OVA inhalation were decreased by administration of PI3K inhibitors. These results suggest that inhibition of vascular endothelial growth factor attenuates peribronchial fibrosis, at least when mediated by regulation of transforming growth factor-β 1 expression through phosphoinositide 3-kinase/Akt pathway in a murine model of allergic airway disease. Copyright",
keywords = "Airway remodelling, Phosphoinositide 3-kinase, Subepithelial fibrosis, Transforming growth factor-β, Vascular endothelial growth factor",
author = "Lee, {K. S.} and Park, {S. J.} and Kim, {S. R.} and Kyung-Hoon Min and Lee, {K. Y.} and Choe, {Y. H.} and Hong, {S. H.} and Lee, {Y. R.} and Kim, {J. S.} and Hong, {S. J.} and Lee, {Y. C.}",
year = "2008",
month = "3",
day = "1",
doi = "10.1183/09031936.00125007",
language = "English",
volume = "31",
pages = "523--531",
journal = "European Respiratory Journal",
issn = "0903-1936",
publisher = "European Respiratory Society",
number = "3",

}

TY - JOUR

T1 - Inhibition of VEGF blocks TGF-β 1 production through a PI3K/Akt signalling pathway

AU - Lee, K. S.

AU - Park, S. J.

AU - Kim, S. R.

AU - Min, Kyung-Hoon

AU - Lee, K. Y.

AU - Choe, Y. H.

AU - Hong, S. H.

AU - Lee, Y. R.

AU - Kim, J. S.

AU - Hong, S. J.

AU - Lee, Y. C.

PY - 2008/3/1

Y1 - 2008/3/1

N2 - Vascular endothelial growth factor (VEGF) is a mediator of airway inflammation and remodelling in asthma. Transforming growth factor (TGF)-β 1 plays pivotal roles in diverse biological processes, including tissue remodelling and repair in a number of chronic lung diseases. However, there are few studies elucidating the interactions between VEGF and TGF-β 1 in allergic airway disease. A murine model of allergic airway disease was used to define the mechanism by which VEGF induces subepithelial fibrosis and to investigate a potential relationship between VEGF and TGF-β 1 and the mechanisms by which VEGF signalling regulates TGF-β 1 expression in allergic airway disease. The ovalbumin (OVA)-inhaled murine model revealed the following typical pathophysiological features of allergic airway disease in the lungs: increased numbers of inflammatory cells of the airways, airway hyperresponsiveness, increased peribronchial fibrosis, and increased levels of VEGF and TGF-β 1. Administration of VEGF inhibitors reduced the pathophysiological signs of allergic airway disease and decreased the increased TGF-β 1 levels and peribronchial fibrosis, including phosphoinositide 3-kinase (PI3K) activity after OVA inhalation. In addition, the increased TGF-β 1 levels and collagen deposition after OVA inhalation were decreased by administration of PI3K inhibitors. These results suggest that inhibition of vascular endothelial growth factor attenuates peribronchial fibrosis, at least when mediated by regulation of transforming growth factor-β 1 expression through phosphoinositide 3-kinase/Akt pathway in a murine model of allergic airway disease. Copyright

AB - Vascular endothelial growth factor (VEGF) is a mediator of airway inflammation and remodelling in asthma. Transforming growth factor (TGF)-β 1 plays pivotal roles in diverse biological processes, including tissue remodelling and repair in a number of chronic lung diseases. However, there are few studies elucidating the interactions between VEGF and TGF-β 1 in allergic airway disease. A murine model of allergic airway disease was used to define the mechanism by which VEGF induces subepithelial fibrosis and to investigate a potential relationship between VEGF and TGF-β 1 and the mechanisms by which VEGF signalling regulates TGF-β 1 expression in allergic airway disease. The ovalbumin (OVA)-inhaled murine model revealed the following typical pathophysiological features of allergic airway disease in the lungs: increased numbers of inflammatory cells of the airways, airway hyperresponsiveness, increased peribronchial fibrosis, and increased levels of VEGF and TGF-β 1. Administration of VEGF inhibitors reduced the pathophysiological signs of allergic airway disease and decreased the increased TGF-β 1 levels and peribronchial fibrosis, including phosphoinositide 3-kinase (PI3K) activity after OVA inhalation. In addition, the increased TGF-β 1 levels and collagen deposition after OVA inhalation were decreased by administration of PI3K inhibitors. These results suggest that inhibition of vascular endothelial growth factor attenuates peribronchial fibrosis, at least when mediated by regulation of transforming growth factor-β 1 expression through phosphoinositide 3-kinase/Akt pathway in a murine model of allergic airway disease. Copyright

KW - Airway remodelling

KW - Phosphoinositide 3-kinase

KW - Subepithelial fibrosis

KW - Transforming growth factor-β

KW - Vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=42949122593&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42949122593&partnerID=8YFLogxK

U2 - 10.1183/09031936.00125007

DO - 10.1183/09031936.00125007

M3 - Article

VL - 31

SP - 523

EP - 531

JO - European Respiratory Journal

JF - European Respiratory Journal

SN - 0903-1936

IS - 3

ER -